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Abstract 
 
Sirtuin1 (SIRT1) is an enzyme that deacetylates histones and several nonhistone proteins including p53 
during stress and plays an important role in the survival of tumor cells. Hereby, this study describes the 
potency of salermide as a SIRT1 inhibitor to induce apoptosis in the MCF-7 and MRC-5 cell lines. MCF7 
and MRC-5 cell lines were cultured in RPMI-1640 and treated with or without salermide at concentration of 
80.56 µmol/L, based on the half-maximal inhibitory concentration (IC50) index at different times (24, 48 
and72 h). The IC50 value was established for the salermide in MCF-7. The percentage of apoptotic cells was 
measured by flow cytometry. Real-time quantitative RT-PCR was performed to estimate the mRNA 
expression of sirtuin1 in MCF-7 and MRC-5 with salermide at different times. ELISA and Bradford protein 
techniques were used to detect endogenous levels of total and acetylated p53 protein generated in MCF-7 
and MRC-5 cells. Our findings indicated that salermide can induce apoptosis in MCF-7 significantly more 
effective than MRC-5 cells. We showed that the expression of SIRT1 was dramatically down-regulated by 
increasing the time of salermide treatment in MCF-7 but not MRC-5 and that the acetylated and total p53 
protein levels were increased more in MCF-7 than MRC-5. Salermide, by decreasing the expression of 
sirtuin1 gene, can induce acetylation of P53 protein and consequently induce significant cell death in MCF-7 
that was well tolerated in MRC-5. 
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INTRODUCTION 
 
Cancer is one of the most important cause 
of mortality in the world population and the 
second leading cause of the death in 
developing countries (1). Breast cancer is the 
most common cancer among females 
worldwide (2). Each year, as estimated, 1.15 
million cases of females worldwide are 
diagnosed with breast cancer while about 
502,000 die from the disease (3). While more 
than half of the cancer cases often have 
mutations in P53 gene (the most important 
tumor suppressor gene), but alterations in 
tumor suppressor genes are not always due to 
mutations. They may also be due to epigenetic 
alteration (4).  
In some diseases such as cancer, often there 
is an imbalance between the expression of 
histone acetyltransferase (HATs) and histone 
deacetylase (HDACs) families. HDACs 
comprise a super family of enzymes involved 
in regulating the lifespan which include 
regulation of transcription (5). HDACs are 
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divided into four different classes (I–IV) based 
on their homology to yeast enzymes (6). Class 
III HDACs were discovered more recently and 
this group of deacetylases were named 
‘sirtuins’ (7). The sirtuins have a nicotine 
adenine dinucleotide (NAD) as a unique 
cofactor to this family that is necessary for the 
removal of the acetyl group from the lysine 
residues (deacetylases function) (8). Other 
HDACs (classic HDACs) use Zn2+ ion for 
deacetylation in a different reaction, although 
the details of this unique biochemical reaction 
is not yet fully understood at the molecular 
level. In human structures of seven different 
NAD dependent deacetylase genes, SIRT1 
(silent information regulator1) to SIRT-7, have 
been recognized (9) and are implicated in the 
control of cellular responses through the 
deacetylation of important regulatory proteins. 
The p53 tumor suppressor protein plays a 
major role in cellular response to DNA 
damage and other genomic aberrations (10). 
Activation of p53 can lead to cell cycle arrest, 
DNA repair and apoptosis. Following DNA 
damage, Human p53 becomes acetylated at 
Lys382. SIRT1 mediates deacetylation of p53 
and negatively regulates the activity of this 
protein (11). 
In normal cells, p53 is a short-lived protein 
due to the activity of Mdm2 (its negative 
regulator), as a ubiquitin ligase, which inhibits 
and destabilizes p53, so p53 levels will be 
undetectable and inactive to induce apoptosis 
(12). In response to various types and stress 
levels which cause DNA damage, HAT family 
mediate acetylation of p53 in C terminus and 
blocks some of the major p53 ubiquitination 
sites by Mdm2 (13). This function leads to p53 
protein stabilization and significant increase in 
the amount and activity of p53 protein in 
human cells (14). It seems that SIRT1 is able 
to deacetylase and inhibit p53 activity and 
suppress the induction of apoptosis and 
prolongs cellular survival in response to DNA 
damage in some cancer cells (15). 
The balance between p53 acetylation 
(positively regulates p53 activity) and 
deacetylation (negatively regulates its activity) 
is mediated by the HATs and SIRT1, and is 
usually well regulated, but the balance is often 
upset in diseases such as cancer (16). Studies 
suggest that pharmacologic inhibition of 
SIRT1 may promote apoptosis by direct 
acetylation of p53 in some cells and can be 
used as an anticancer strategy (17). Some 
reports suggest that SIRT1 probably mediates 
p53 deacetylation and inhibits p53, thereby 
prevents apoptosis in response to various types 
of stress in some of malignancies (18). These 
effects can be reversed in cancer cells by 
inactivation of SIRT1. The human breast 
carcinoma cell line MCF-7 has wild-type p53 
(19) but this tumor suppressor gene due to 
epigenetic events, is not functional and is 
unable to induce apoptosis (20). Some 
researches have shown that in certain type of 
cancerous cell lines SIRT1 inhibitors could 
induce p53 acetylation as an antitumor effect 
(21). 
We assumed that the apoptotic effect of this 
drug is different in normal and cancer cells. 
However, little is known about the 
mechanisms of cellular targets of sirtuin1 gene 
(22). In this study we investigated apoptotic 
effects of salermide, as the inhibitor of sirtuin1 
in MCF-7 (breast adinocarsinoma) and MRC-5 
(lung fibroblasts as non-tumorigenic control) 
cell lines. 
 
MATERIALS AND METHODS 
 
Cell lines, drug treatment and culture 
condition 
Human breast carcinoma cell line (MCF-7) 
and human lung fibroblasts cell line (MRC-5) 
were purchased from the National Cell Bank 
of Iran-Pasteur Institute. Salermide (N-{3-[(2-
hydroxynaphthalen-1- ylmethylene )- amino ]-
phenyl} -2-phenylpropionamidea) (Fig. 1) as 
the inhibitor of sirtuin1, was purchased from  
 
 
 
Fig. 1. Structures of Salermide (N-{3-[(2-hydroxy-
naphthalen-1-ylmethylene) - amino] -phenyl}-2-phenyl-
propionamide) 
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GAPDH: Glyceraldehyde3-phosphatedehydrogenase, as 
endogenous control 
 
Sigma (USA). All Cell lines used in the 
present study were cultured in RPMI-1640 
medium (Sigma) supplemented with 10% fetal 
bovine serum (FBS, Sigma) and 1% penicillin-
streptomycin (Sigma), at 37°C and in 
humidified atmosphere containing 5% CO2. 
Salermide was dissolved in stock solutions and 
for treatments; the compounds were diluted in 
DMSO to appropriate concentrations 
according to the reported procedures (23). 
When cells became >80% confluent and 
growing exponentially in 10 cm diameter 
culture dishes, 105 cells (MCF-7 or MRC-5) 
were counted and plated in 3-cm diameter 
culture dishes for 24 h in RPMI-1640 culture 
medium before they were incubated with 
certain concentrations of salermide, based on 
IC50 index, at different times (24, 48 and 72 
h). Photography was done for cultures before 
and after treatment with salermide at different 
times using inverted microscope (Nikon, TE 
2000-U, Japan) (24). 
 
IC50 assay   
After 24 h of the treatment, the IC50 value 
for salermide in MCF-7 group was determined. 
Briefly, 104 Cells (MCF-7) were counted and 
placed into each well of a 24-well micro plate 
and were treated with various drug concen-
trations (0, 6.25, 12.5, 25, 50, 100, 150, 200 
µM ) for 24 h and the MTT survival assay was 
then carried out for the evaluation of the cell 
viability with different drug concentration. A 
plot of viability versus drug concentration was 
used to calculate IC50 values for MCF-7 cell 
line (5). 
 
Flowcytometric analysis 
The percentage of apoptotic cells was 
measured by flow cytometry following 
AnnexinV (FL1-H) and PI (FL2-H) labeling.. 
A minimum of 5×105cells/ml were analyzed 
for each sample. Cells were treated with 
salermide (80.56 µg/ml) for 24, 48 and 72 h, 
then washed in PBS and resuspended in 
Binding buffer (1x). After the additionof 5 µl 
AnnexinV-FITC to 195 µl cell suspension the 
analysis was carried out according to the 
manufacturer’s protocol (BMS500F1/100CE 
AnnexinV-FITC, eBiscience, USA), Finally 
the apoptotic cells were counted by FACScan 
flow cytometry (Becton Dickinson, Heidelberg, 
Germany). These experiments were carried out 
in triplicate and independently repeated at least 
three times (25). 
 
Reverse transcription and real-time PCR 
analysis 
Real-time quantitative RT-PCR was 
performed to quantitatively estimate the 
mRNA expression of sirtuin1 in MCF-7 and 
MRC-5 cells before and after treatment with 
salermide at different times. Total RNA was 
isolated by RNeasy mini kit (Qiagen), treated 
by RNase free DNase (Qiagen) to eliminate 
the genomic DNA. The RNA concentration 
was determined using a Biophotometer 
(Eppendorf). Total RNA (100 ng) was reverse-
transcribed to cDNA by using the RevertAid™ 
First Strand cDNA Synthesis Kit (Fermentas) 
according to the manufacturer’s instructions. 
Real-time RT-PCR was performed by the 
Maxima SYBR Green Rox qPCR master mix 
kit (Fermentas). Primer sequences are shown 
in Table1. Real-time PCR reactions were 
performed using the Steponeplus (Applied 
Biosystem). The PCR amplification conditions 
consisted of 10 min at 95ºC followed by 40 
cycles of denaturation step at 95ºC for 15 sec 
and annealing and extension for 1 min at 60 
ºC. Data were analyzed using the comparative 
Ct (∆∆ct) method, the relative expression level 
of SIRT1 was calculated by determining a 
ratio between the amount of SIRT1 and that of 
endogenous control. Melting curve analysis 
(60ºC → 95ºC increment at 0.3ºC) was used to 
determine melting temperature of specific 
amplification products and primer dimmers. 
These experiments were carried out in 
triplicate and independently repeated at least 
three times (26). 
 
Bradford protein assay 
Total (intracellular) protein concentration 
was determined by Bradford method. This  
Table1. Primers used in real-time PCR  
Primer sequences Primer ID  
TGGCAAAGGAGCAGATTAGTAGG  SIRT1-F  
CTGCCACAAGAACTAGAGGATAAGA  SIRT1-R  
AAGCTCATTTCCTGGTATG  GAPDH-F  
CTTCCTCTTGTGCTCTTG  GAPDH-R  
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Fig. 2. IC50 assay for the analysis of half-maximal 
inhibitory concentration of Salermide in MCF-7 cancer 
cell lines after 24-h of treatment. Cells were incubated 
with or without Salermide using 0, 6.25, 12.5, 25, 50, 
100, 150 and 200 µM doses and the relative amount of 
viable cells were estimated by measuring the 
absorbance of the cell suspension after incubation with 
MTT. The graph of viability versus drug concentration 
was used to calculate IC50 values base on trend line 
equation (Y=-0.260X + 87.06) for MCF-7 cell line 
(80.56 µM). 
 
method was carried out before the ELISA 
assay. Total Protein was extracted from MCF-
7 and MRC-5 cells before and after salermide 
treatment as described in ELISA assay. Bovine 
serum albumin (BSA) was used to prepare 
protein standards at nine concentrations (0.25, 
0.5, 1, 1.5, 2, 3, 4, 5 and 6 mg/ml). Absorbance 
was measured at 595 nm using a spectro-
photometer (Bausch & lomb70, Germany) (27). 
 
Acetylated and total p53 sandwich ELISA 
assay 
Enzyme linked immunosorbent assay 
(ELISA) was used to detect specifically 
endogenous levels of total and acetylated p53 
protein generation in MCF-7 and MRC-5 cells 
in presence or absence of salermide at 
different incubation times (24, 48 and 72 h). 
Acetylated and total p53 ELISA Kit were 
obtained from Cell Signaling Technology 
(Cat.No.7236 & 7370). To extract the proteins 
cells were lysed first. Briefly, after treatment 
with salermide cells were harvested and media 
was removed. Cells were then rinsed with ice-
cold PBS and after removal of PBS 0.5 ml of 
ice-cold Cell Lyses Buffer (CST.Cat.No. 
9803) with 1 mM phenylmethylsulfonyl 
fluoride (PMSF) was added to each plate and 
incubated on ice for 5 min. Cells were scraped 
off the plate and transferred to an appropriate 
tube and a freeze-and-thaw cycle was 
performed three times to further disrupt the 
cell membrane. Tubes were then centrifuged 
for 10 min at 4°C and the supernatant was 
transferred to a new tube. This supernatant was 
the cell lysate and was used for the ELISA and 
protein assays. Sandwich ELISA was 
performed according to the manufacturers’ 
protocol. Absorbance was measured using an 
ELISA reader (Hyperion, Germany) at 450 
nm. The absorbance of each sample was 
divided by the absorbance of the untreated cell 
with the same incubation time to calculate a 
control index. All experiments were carried 
out in triplicate (28). 
 
Statistical analysis 
All the quantitative data were presented as 
the mean ± standard deviations. Kolmogorov-
Simonov test was used for assessing normal 
distribution of variables. One-way-analysis of 
variance (ANOVA) with LSD post hoc test 
was performed to determine statistical 
significance among different groups by using 
SPSS software package16.0. Significance was 
accepted at P<0.05. 
 
RESULTS 
 
IC50 
After the treatment of MCF-7 cells with 
MTT solution, the dark blue formazan crystals 
were seen in the cells, which indicated their 
metabolic activity. The reduction in the 
number of cells was dependent on the cell type 
as shown by the IC50 index (half-maximal 
inhibitory concentration). The IC50 values for 
the salermide were established (Fig. 2). The 
results showed that the essential salermide 
concentration to achieve the IC50 in MCF-7 
cells at 24 h was 80.56 µmol/L (Fig. 1).  
 
Flow cytometry 
To establish the anticancer potential of 
salermide, we first investigated the effects of 
this SIRT1 inhibitor on the proliferation of the 
breast carcinoma cell line (MCF-7). The flow 
cytometry results showed that based on IC50 
index salermide at concentration of 80.56 
µmol/L could significantly induce apoptosis in 
MCF-7 cells that increased with time (Fig. 3A, 
3B). Salermide treatment arrested MCF-7 cell 
proliferation (≥95% of inhibition)  
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Fig. 3. Relative levels of apoptotic cells in MCF-7 and MRC-5cells treated with 80.56 µM/L Salermide for different 
times. Cells incubated with the vehicle (DMSO) were used as a control. A. The percentage of apoptotic cells was 
measured using the AnnexinV FITC and PI assay. ***P<0.001 vs. All other groups of MCF-7 cells treated with 
Salermide. **P<0.05 vs. 0, 24 and 48 h groups of MRC-5 Cells. *P<0.05 vs. All other groups of MCF-7 Cells 
incubated with the vehicle (DMSO). B. MCF-7and MRC-5 cells were treated with 80.56 µM/L of Salermide, and 
apoptosis was measured by flow cytometry following AnnexinV (FL1-H) and PI (FL2-H) staining. Cells that are 
AnnexinV-positive and Propidium iodide negative are in early apoptosis, as phosphatidylserine (PS) translocation has 
occurred, although the plasma membrane remains intact. Cells that are positive for both AnnexinV and PI are either in 
the late stages of apoptosis, as PS translocation has occurred and the loss of plasma membrane integrity is visible.   
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Fig. 4. Inverted microscopy images of MCF-7and MRC-5 cells before and after treatment with 80.56 µmol/L Salermide 
and control DMSO at different times. Magnification, × 20 
 
at 72 h whereas its inhibition of MRC-5 cells 
proliferation at all incubation times studied 
was negligible. Although its apoptotic effect at 
24 h and 48 h of the treatment was higher than 
untreated sample (P<0.05) (Fig. 3A, 3B), at 72 
h its apoptotic effect was decreased in MRC-5 
cells even if not statistically significant 
(P>0.05) (Fig. 3A, 3B). MCF-7 apoptotic cells  
showed a sharp increase at all times in 
comparison with MRC-5 cells. In the control 
samples that DMSO (salermide solvent) was 
used, a slight but non significant cell death in 
both cell lines was observed (P>0.05) at 
various times (Fig. 3A, 3B). These results 
were supported by morphologic examinations 
using inverted microscope (Fig. 4). 
 
Real-time PCR 
To examine the hypothesis that apoptotic 
induction in cancer cell line by salermide 
required the suppression of sirtuin1 gene 
expression, we used two cell lines, MCF-7 as 
cancer cell line and MRC-5 as noncancerous 
cell line. We examined the inhibitory effect of 
80.56 µmol/L salermide on the mRNA 
expression of Sirtuin1 in MCF-7 and MRC-5 
cells using real-time PCR. The SIRT1 gene 
expression was dramatically down-regulated 
by salermide treatment with time in MCF-7 
cells, in particular, at 72-h treatment its 
expression was fully suppressed (Fig. 5, 
P<0.01). In MRC-5 cells the expression of 
SIRT1 was also significantly reduced at all 
treatment times but the difference in the 
expression among different times were not 
statistically significant (P>0.05) (Fig. 5). 
However, the effect of salermide treatment on 
down-regulation of SIRT1 expression was 
significantly higher in MCF-7 cells in 
comparison with MRC-5 cells (Fig. 5). 
 
Bradford protein  
The Bradford assay was carried out to 
determine the total protein concentration in 
MCF-7 and MRC-5 cell lysates at 48 h 
treatment with salermide. The standard curve 
was linear in the range of 0.25 to 6 mg/ml of 
BSA. The total protein concentration for 
MRC-5 and MCF-7 was respectively 4.48 and 
5.17 µg/ml)  
 
Acetylated and total p53 Sandwich ELISA  
To investigate further the effects of 
salermide (SIRT1 inhibitor) on cell apoptosis, 
the ELISA analysis was performed in MCF-7 
(wild-type p53) and MRC-5 cells. The cells 
MCF-7cells, Salermide treatment 
72 h (magnification, ×20) 
MCF-7cells, Salermide treatment 
24 h (magnification, ×20) 
MCF-7cells, Salermide treatment 
48 h (magnification, ×20) 
MRC-5cells, no treatment 
(magnification, ×20) 
MRC-5cells, Salermide treatment 
72 h (magnification, ×20) 
MCF-7cells, DMSO treatment   
72 h (magnification, ×20) 
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Fig. 5. Results of Real-time quantitative PCR on the Sirtuin1 mRNA expression in MCF-7 and MRC-5 cells before and 
after Salermide treatment at different times. Relative expression levels of each gene were obtained by using the 
Comparative Ct (∆∆ct) method. SIRT1 inhibitor caused epigenetically silenced sirtuin. 1Values were the means of 
triplicate experiments **P<0.001 vs. Control (non-treated Salermide) and other MCF-7 groups. *P<0.05 vs. MRC-5, 
24h and Control group. 
 
 
                                         A 
 
 
                                           B 
 
Fig. 6. The results of ELISA assay of total and acetylated p53 protein generated in MCF-7 and MRC-5 based on control 
index. Cells were treated with 80.56 µmol/L of Salermide for 0, 24, 48 and 72 h. Values are the means + SD for 
triplicate experiments. (A) *P<0.001 vs. all other groups in different times. (B) *P<0.001 vs. all other groups in 
different times. **P<0.05vs. Total P53 in MRC-5 without Salermide treatment and with Salermide treatment at time 24 
and 48 h. No significant difference was shown in total and acetylated p53 content of in other groups. 
 
were treated with 80.56 µmol/L salermide for 
different length of time (0, 24, 48 and 72 h), to 
study its effects on the acetylation status of the 
p53 as target of SIRT1. The results of ELISA 
analysis was calculated based on control 
index. The results showed that, salermide 
could induce p53 acetylation in MCF-7 and 
MRC-5 cells and that significant increase in 
total protein levels with time was observed 
until 48 h of the treatment in MCF-7 cells but 
not in MRC-5 cells (P<0.05). Interestingly, 
between 48 and 72 h, a decrease of protein 
levels was observed in MCF-7 cells (Fig. 6A). 
After treatment by salermide at different times, 
the acetylated P53 protein levels in MCF-7 
cells, was significantly higher than in MRC-5 
cells (P<0.05) (Fig. 6A). We also performed 
the above method to examine the total p53 
protein level in both cell lines. These results 
were similar to the above results of acetylated 
p53 except for a significant rise in total P53 
protein levels in MRC-5 cells with increasing 
time until 48 h (P<0.05) (Fig. 6B). In control 
samples using DMSO (as salermide solvent) 
had a negligible effect on inducing total and 
acetylated p53 in both cell lines at the different 
time of study (Fig. 6A, 6B). 
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DISCUSSION 
 
We have studied the potency and functional 
mechanism of the recently developed SIRT1 
inhibitor (salermide) at a concentration 
according to IC50 on MCF-7 as the breast 
cancer cell line and MRC-5 as a non-
tumorigenic control cells. Salermide IC50 
result was similar to the previously published 
data on the efficiency of salermide on SIRT1 
in breast cancer cells(MDA-MB-231) (5). 
Previous studies have shown that this 
compound can inhibit NAD-dependent 
deacetylases in mammalian cells (23). In 
recent years, several researchers have 
described the apoptotic effect on HDAC (class 
III) inhibitors and have shown that these 
effects depend on the type of cancerous cells 
(29,30).  
The role of SIRT1 is complex during stress 
and its inhibitory effect is likely to be cell 
context specific (31). Specific explanations 
regarding the molecular mechanisms for most 
of sirtuin inhibitors (particularly salermide) in 
different cancerous and normal cell lines and 
in relation to time is lacking. In this study we 
examined the apoptotic potency of salermide, 
using the MCF-7 breast carcinoma cell line 
because this cell line has substantial 
expression level of SIRT1, has mainly wild-
type p53 genes and this type of cancer is the 
most prevalent malignancy in woman. In this 
study, treatment by 80.56 µM salermide at 
different times showed a time-dependent 
increase in apoptotic cells count of the 
cancerous cells but not in non-tumorigenic 
MRC-5 cells as measured by flow cytometric 
assay. On the other hand although salermide 
can effectively induce inhibition of SIRT1 and 
subsequent cancer cell death, it does not have 
such effect on the fibroblastic cells. These 
results revealed that the apoptotic sensitivity of 
MRC-5 cells to salermide was negligible. This 
is in accordance with findings of Lara and 
coworkers (5) who showed that sirtuin 
inhibitors can induce massive apoptosis in 
cancerous but not in nonmalignant cells. We 
observed the strongest apoptotic effect in 
MCF-7 cells after 72 h of incubation with 
salermide, in that only 10% of MCF-7 cells 
were viable while at this time MRC-5 cells 
showed only a slight increase in level of 
apoptosis (only 10-20%). It seems that this 
observation in MCF-7 cells is due to the 
presence of the wild-type p53, since MDA-
MB-231 breast cancer cells (mutant-P53) 
shows only a small increase of apoptotic 
response to salermide (5). 
Therefore, it seems that in MCF-7 cells 
SIRT1 promotes cell survival and salermide 
alone can induce apoptosis in this cancer cell 
with wild-type p53 in a time-dependent 
manner. Our results are in close agreement 
with the findings of Zou and coworkers (32) 
who have shown that TSA (HDAC inhibitor) 
can induce apoptosis in BGC-823 gastric cell 
line in a time-dependent manner. Also our 
results are consistent with the findings of 
Solomonand coworkers (33) that SIRT1 may 
be an important regulator of wild-type p53 
function and small molecule inhibitors of 
SIRT1 may act as anticancer agents. We 
observed that salermide is ineffective in 
promoting P53 acetylation and hence is unable 
to activate P53 to induce apoptosis in 
fibroblastic cells. This finding is supported by 
morphological examination using inverted 
microscope. 
Once we determined that salermide 
antitumor activity was primarily because of the 
promotion of apoptosis, we decided to study 
the molecular mechanisms involved in this 
process. We first studied the expression of 
SIRT1 in salermide-mediated apoptosis using 
Real time PCR. The results of Real time PCR 
assay indicated that salermide mediated 
inhibition of sirtuin1 expression in a time-
dependent manner in MCF-7 cells. We also 
found that sirtuin1 expression levels in MRC-5 
cells was low and after the treatment with 
salermide slightly decreased in a time 
dependent manner. Importantly, we found that 
in the noncancerous cells, SIRT1 silencing due 
to salermide was at least equivalent to MCF-7 
breast cancer cells. Subsequently, we observed 
that SIRT1 silencing occurred particularly 
after 48 h of salermide treatment in MCF-7 
cells. However, SIRT1 silencing had no 
apparent effect on the cell growth or viability 
of the noncancerous cells. This is in close 
agreement with the findings of other 
investigators (34-38) that, in the absence of 
applied stress, SIRT1 silencing induces growth 
arrest and/or apoptosis in human epithelial 
Apoptotic effects of sirtuin1 inhibitor on MCF-7 and MRC-5  
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cancerous cells. In contrast, normal human 
epithelial cells and normal human diploid 
fibroblasts seem to be refractory to SIRT1 
silencing. This is in apparent disagreement 
with the findings of Peck and coworkers (19) 
who described that knockdown of SIRT1 using 
siRNA-silencing assay did not affect the 
growth of the cancerous cells in comparison to 
the controls. However, these data can explain 
the failure of salermide to induce cell death in 
MRC-5 cells.  
These results indicated that the constitutive 
function of SIRT1 differs in MCF-7 and 
MRC-5 cells and that SIRT1 enables MCF-7 
cancer cell viability, but is not essential for the 
viability of lung fibroblast cells. These results 
are also similar to the study of Kojima and 
coworkers (26) who noted that the up-
regulation of SIRT1 expression was observed 
in breast cancer MCF-7 cells and that 
treatment with a SIRT1 inhibitor, Sirtinol, 
induced inhibition of SIRT1 expression and 
subsequently inhibited cell growth in human 
prostate cancer cell lines. Importantly, in 
MRC-5 cells we observed that after 48h of 
treatment, SIRT1 mRNA levels started to rise 
so that the effect of 72-h of treatment of MRC-
5 cells by salermide was similar to the non-
treatment condition. Subsequently, we used 
real time PCR to evaluate the SIRT1 
expression in both cell lines before the 
treatment and we observed over-expression of 
SIRT1 in MCF-7 cells compared to MRC-5 
cells. This increased level of SIRT1expresion 
in MCF-7 cells presumably inhibit apoptosis 
and mediate survival in response to stress. This 
finding is in accordance with the findings of 
Sun and coworkers (39) that reported over 
expression of sirtuin1 in breast carcinoma. Our 
findings indicated that the induction of cell 
death by SIRT1 inhibitor required the 
inactivation of SIRT1 gene so these findings 
show its potential antitumor effects. A recent 
study by Calvanese and coworkers (40), has 
discussed the implications of similar findings 
on sirtuin inhibition based cancer treatment 
and application of sirtuin activation for 
anti‐aging therapy. A number of previous 
studies have reported that SIRT1 inhibition 
could induce (24,41) or not induce (42) p53 
acetylation in cancer cell lines. We observed a 
direct correlation between total and acetylated 
P53 protein levels and salermide toxicity in the 
MCF-7 cell line. These results suggest that 
incubation of MCF-7 with salermide could 
induce hyperacetylation of p53 protein and 
apoptosis in MCF-7 cells. Our results 
indicated a slightly decrease of total and 
acetylated p53 at 72 h of incubation in MCF-7 
cells. We presume that, although increase in 
total and acetylated p53 levels in response to 
SIRT1 silencing occurs at this time, this 
increase is undetectable by ELISA assay 
because of the release of proteases and 
activation of degradation processes inside the 
cancer cells after 48 h of cell death. These 
findings show that although in MCF-7cells 
P53 was wild-type, however, it was a target for 
deacetylation by SIRT1and so, could not 
induce apoptosis due to this aberrant 
epigenetic event.  
These data are in accordance with the 
findings of Pruitt and coworkers (43) who 
reported that SIRT1 is a cancer-related gene 
and inhibits p53 function through epigenetic 
changes. Our findings suggest that acetylation 
of wild-type p53 as a tumor suppressor leads 
to activation of apoptotic program and is an 
integral part of cytotoxic activity of salermide 
to induce massive apoptosis in less than 24h 
treatment in MCF-7 cells (44). The role of 
SIRTs in drug resistance may be foremost 
related to their ability to target and modulate 
the activity of tumor suppressors, including 
p53. This finding further support the 
theoretical assumption that SIRT1 inactivation 
is required for the cell death induction and p53 
acetylation in cancer cells only for wild-type 
p53 and salermide neither triggers cell death 
nor p53 acetylation in normal cells. Our results 
is also in agreement with the studies of Kamel 
and coworkers (45), Matsushita and coworkers 
(46) and Heltweg and coworkers (24) who 
suggested that SIRT inhibitors are targets for 
SIRT1and SIRT2 and p53 acetylation is 
important for the cell death induction. 
Huhtiniemi and coworkers (47) has shown that 
salermide is ineffective in inducing apoptosis 
in cells with functional p53 expression (wild-
type p53) which is in contrast to our findings. 
Intriguingly, Salermide can induce apoptosis 
without increasing p53 acetylation in SW480 
cells (5). Treatment with chemotherapeutic 
drugs also induce cell death indistinguishable 
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from that triggered by silencing of SIRT1 (48) 
that is also accompanied by p53 acetylation 
suggesting that SIRT inhibitors, such as 
salermide, function through common pathways 
and mediated their cytotoxic effects through 
targeting p53 and its acetylation. 
 
CONCLUSION 
 
A hypothesis is formulated that SIRT1 is 
aberrantly recruited to proapoptotic proteins in 
cancer but not in normal cells and as a 
consequence of this; P53 is aberrantly 
repressed in MCF-7 cells. The treatment with 
salermide would induce apoptosis 
predominantly through the inhibition of SIRT1 
and consequent hyperacetylation and 
reactivation of tumor suppressor P53 to 
induced cell death in MCF-7cells. In this study 
we describe that salermide represent a 
potential for cancer therapy that has a strong 
inhibitory activity on sirtuin1. It induces 
massive apoptosis in MCF-7 cancer cells but 
not in noncanceric cells. This makes it a 
promising novel class of antitumorigenic drugs 
that target acetylation of proteins that are 
epigenetically repressed by SIRT1 exclusively 
in cancer cells. 
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